UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 9/28/2018 |
| Start Date: | July 2014 |
| End Date: | August 2018 |
We propose a novel intervention for reducing BP that could have a preferential impact in
patients with hyperuricemia and gout. There is a great need for new anti-hypertensives,
particularly among those with gout. The proposed study is novel in its plans to investigate
the physiologic mechanisms through which urate contributes to vascular disease and by which
ULT may contribute to BP reduction. Also innovative, we will: 1) determine to what extent the
described benefit of lowering serum urate extends beyond the adolescent population previously
studied into young adults, 2) test whether a urate-lowering approach will benefit individuals
that do not yet meet the current definition of hyperuricemia and do not have gout, and 3)
begin to explore potential mechanisms for the higher prevalence of hypertension among
African-Americans. If successful, this work could translate to the standard of clinical care
and to health care recommendations for the population as a whole.
patients with hyperuricemia and gout. There is a great need for new anti-hypertensives,
particularly among those with gout. The proposed study is novel in its plans to investigate
the physiologic mechanisms through which urate contributes to vascular disease and by which
ULT may contribute to BP reduction. Also innovative, we will: 1) determine to what extent the
described benefit of lowering serum urate extends beyond the adolescent population previously
studied into young adults, 2) test whether a urate-lowering approach will benefit individuals
that do not yet meet the current definition of hyperuricemia and do not have gout, and 3)
begin to explore potential mechanisms for the higher prevalence of hypertension among
African-Americans. If successful, this work could translate to the standard of clinical care
and to health care recommendations for the population as a whole.
Inclusion Criteria:
- Pre-hypertension or stage I hypertension, defined as the following after the mean of
two clinic measurements:
- Systolic blood pressure (SBP) ≥ 120 and <160 or;
- Diastolic blood pressure (DBP) ≥ 80 and < 100
- Serum urate ≥ 5.0 mg/dL for men or ≥ 4.0 mg/dL for women
- Age 18-40
Exclusion Criteria:
- Any current pharmacological treatment for hypertension, including diuretics
- Estimated glomerular filtration rate < 60 mL/min/1.73m2
- Current use of any urate-lowering therapy or statins
- Prior diagnosis of gout or past use of urate-lowering therapy for gout
- Prior diagnosis of diabetes
- Pregnancy, or recent delivery or last trimester pregnancy loss more recent than 3
months
- Active smokers
- Immune-suppressed individuals including transplant recipients or current use of
azathioprine.
- Leucopenia with absolute white cell count < 3000 /mL, anemia with hemoglobin < 12
g/dL, or thrombocytopenia with platelet count < 150,000/mL
- Individuals of Han Chinese or Thai descent with HLAB5801 genetic phenotype
- Serious medical condition that at investigator's judgment precludes utilization of a
fixed dose of allopurinol
We found this trial at
1
site
1720 2nd Ave S
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 934-4011
Principal Investigator: Kenneth G Saag, MD, MsC
Phone: 205-996-6086
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
